Ioxilan Production Cost Reports

The report provides a detailed analysis essential for establishing an Ioxilan production plant. It encompasses all critical aspects necessary for Ioxilan production, including the cost of Ioxilan production, Ioxilan plant cost, Ioxilan production costs, and the overall Ioxilan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Ioxilan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ioxilan is a contrast agent primarily used in medical imaging, especially in procedures like computed tomography (CT) scans and angiography. It helps enhance the visibility of blood vessels, tissues, and organs during procedures such as X-rays, CT scans, and angiography. It belongs to a group of iodinated contrast media that are commonly used in diagnostic imaging to improve the quality of the images. It is generally injected into the body to make it easier for doctors to detect abnormalities like blockages, tumours, or other vascular issues. It is commonly used in both diagnostic and interventional radiology to assist in imaging the heart, brain, kidneys, and other organs. It is often used in the imaging of the brain, chest, and abdominal regions to diagnose conditions like strokes, tumours, and gastrointestinal disorders. Moreover, Ioxilan is also involved in research, where it is used to study vascular structures and tissue perfusion.

The demand for Ioxilan is predominantly driven by its application as a contrast agent to enhance the visibility of blood vessels and organs during diagnostic imaging, which boosts its market growth. Its application in diagnostic procedures such as X-rays, CT scans, and angiography to detect abnormalities significantly boosts its demand in modern diagnostic centres. Its usage in both diagnostic and interventional radiology to assist in imaging the heart, brain, kidneys, and other organs also promotes its demand in the medical diagnostics and radiology sectors. Its application as an important contrast agent in procedures like coronary angiography, where detailed images of blood vessels are required, also contributes to its demand in the medical and diagnostic sectors.

Its demand as a safer choice of contrast agent in diagnostic imaging due to its lower risk of causing side effects compared to other contrast agents also drives its market expansion. Furthermore, advancements in production techniques, supply chain efficiency, supplier reliability, and environmental sustainability practices are major factors that impact global procurement of Ioxilan. Industrial Ioxilan procurement is influenced by factors such as the cost and availability of raw materials, regulatory approvals, and compliance with safety standards.

Raw Material for Ioxilan Production

According to the Ioxilan production plant project report, the major raw materials for Ioxilan production includes 5-amino-N-(2-hydroxyethyl)-2,4,6-triiodoisophthalamic Acid.

Production Process of Ioxilan

The extensive Ioxilan production cost report consists of the following industrial production process:

1. Production via Acylation & Amidation: The production process of Ioxilan begins with the acylation of 5-amino-N-(2-hydroxyethyl)-2,4,6-triiodoisophthalamic acid using an acylating agent, such as acetic anhydride, in the presence of a solvent and a catalyst. Then, the acylated product is converted into an acyl chloride using thionyl chloride in the second step. In the third step, the acyl chloride reacts with 3-amino-1,2-propanediol to form the corresponding amide. Finally, the amide undergoes N-alkylation with 3-chloro-1,2-propanediol to introduce the second 2,3-dihydroxypropyl group. Further, the crude Ioxilan is isolated and purified through recrystallisation or column chromatography.

Ioxilan is a low-osmolar nonionic triiodinated diagnostic contrast agent used in various radiographic imaging procedures such as angiography, urography, and computed tomographic scans. In its pharmaceutical formulation, it appears as a clear, colourless to pale yellow solution that is highly water-soluble and contains no undissolved solids. The compound is non-ionic and does not dissociate in solution, and it demonstrates good chemical stability at room temperature without crystallisation. The molecular formula of the compound is C18H24I3N3O8, and its molecular mass is 791.12 g/mol. Ioxilan was marketed under the trade name Oxilan for intravascular administration and works by causing opacification of vessels to permit radiographic visualisation of internal body structures. Inappropriate administration of this contrast agent may cause serious health problems such as contrast-induced nephropathy, allergic or hypersensitivity reactions, cardiovascular complications, including arrhythmias and hypotension. In severe cases, it can also cause anaphylactic shock or renal failure, particularly in patients with pre-existing kidney dysfunction.